Scientists have identified a new way some cancers dodge destruction: a notorious tumor-driving protein appears to help damaged cancer cells patch themselves back together after chemotherapy and radiation.
Researchers report that MYC, already known for pushing aggressive cell growth, may also move directly to sites of broken DNA and call in the machinery needed for repair. That matters because many cancer treatments work by inflicting enough DNA damage to kill tumor cells. If MYC helps fix that damage, it could give cancers a powerful survival advantage just when treatment should hit hardest.
The finding reframes MYC not just as a driver of tumor growth, but as a potential shield against the very therapies designed to stop it.
The discovery adds a sharper edge to a longstanding problem in oncology: why some tumors shrink under treatment, then return. Reports indicate MYC may help cancer cells recover from the genetic injuries caused by chemotherapy and radiation, allowing at least some cells to endure and keep dividing. That does not by itself rewrite cancer care, but it offers a clearer explanation for treatment resistance in cancers where MYC plays a central role.
Key Facts
- Researchers found MYC may go directly to broken DNA in cancer cells.
- The protein appears to recruit repair machinery that helps fix treatment-related damage.
- Chemotherapy and radiation often aim to kill cancer by causing DNA breaks.
- The findings suggest MYC could help explain why some tumors survive and return.
The work also points toward a practical next step. If future studies confirm that MYC helps coordinate DNA repair, drug developers may look for ways to block that function and leave tumor cells more exposed to treatment. For patients, the significance lies in what could come next: more precise strategies to prevent resistance, improve response to chemotherapy and radiation, and make cancer therapies harder for tumors to outlast.